AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
SciSparc's 15min chart signals overbought conditions and KDJ death cross.
ByAinvest
Tuesday, Sep 30, 2025 10:32 am ET2min read
According to the 15-minute chart for SciSparc, the RSI indicator has reached an overbought level, and the KDJ indicator has formed a death cross at 09/30/2025 10:30. This suggests that the stock price has experienced a rapid increase, potentially exceeding the underlying fundamentals, and momentum is shifting towards a decline, potentially leading to further decreases in the stock price.
SciSparc Ltd. (SPRC) stock has experienced a significant surge in the past few days, with the price rising by over 50% in premarket trading on Tuesday, September 29, 2025. The stock's performance can be attributed to two major developments: the approval of the acquisition of its subsidiary, MitoCareX Bio Ltd., by N2OFF Inc. (NITO), and the announcement of a groundbreaking quantum computing initiative in drug discovery.Acquisition Approval
The approval of the acquisition by N2OFF shareholders has paved the way for the completion of the deal. Under the agreement, N2OFF will purchase 6,622 shares of MitoCareX from SciSparc for $0.7 million and exchange the outstanding shares of MitoCareX with all Sellers for N2OFF's common stock, totaling 40% of N2OFF's fully diluted capital stock. The transaction is expected to close in the first half of October. Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, with N2OFF appointees on the board. The agreement also requires N2OFF to commit to financially supporting MitoCareX's operations post-closure for the first two years, including a cash investment of $1 million [1].
Quantum Computing Initiative
In addition to the acquisition news, SciSparc announced a bold initiative to leverage quantum computing in drug discovery. The company aims to improve the accuracy of 3D protein modeling and drug discovery processes by leveraging quantum technology. This initiative positions SciSparc at the forefront of innovation in structural biology and personalized medicine, promising significant advancements in the treatment of neurological and rare diseases [2].
The initiative aims to develop new quantum-enabled tools for understanding protein structures and their interactions with drugs. Quantum computing offers a revolutionary way to simulate energy dynamics and protein folding with unprecedented accuracy, making it possible to predict how proteins interact with potential drugs more precisely. This advancement is crucial as proteins, the building blocks of life, are dynamic and constantly shifting between different shapes. Traditional computing struggles to model these changes, limiting the accuracy of drug discovery processes [2].
Technical Indicators
According to the 15-minute chart for SciSparc, the Relative Strength Index (RSI) indicator has reached an overbought level, and the KDJ indicator has formed a death cross at 10:30 on September 30, 2025. This suggests that the stock price has experienced a rapid increase, potentially exceeding the underlying fundamentals, and momentum is shifting towards a decline, potentially leading to further decreases in the stock price [3].
Conclusion
SciSparc's stock surge can be attributed to the positive developments in the acquisition of its subsidiary and the launch of a groundbreaking quantum computing initiative in drug discovery. While the stock's rapid increase may suggest overbought conditions, investors should closely monitor the company's progress and the potential impact of these initiatives on its long-term prospects.
References
[1] https://www.nasdaq.com/articles/scisparc-stocks-surge-50-pre-market-after-n2off-approves-mitocarex-acquisition
[2] https://parameter.io/scisparc-ltd-sprc-stock-soars-50-on-bold-move-into-quantum-powered-drug-discovery/
[3] https://www.stocktitan.net/news/SPRC/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet